Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 29Fallopian Tube Neoplasms 15Breast Neoplasms 10Carcinoma, Ovarian Epithelial 6Peritoneal Neoplasms 3Multiple Myeloma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Kaposi 1Pelvic Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Low Grade Serous Ovarian Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Genital Neoplasms, Female 1Genetic Predisposition to Disease 1Endometrial Neoplasms 1Carcinoma 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

taxane 1liposomal doxorubicin 1Sorafenib 1Paclitaxel 1Docetaxel 1Cisplatin 1Biosimilar Pharmaceuticals 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Vaccinia × liposomal doxorubicin × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡